back to search
Trial Reference/Name Tumor Stream/s Age Location Short Title Eligibility Criteria Trial Open
ABTR06C1 [COG-ABTR06C1]
 Malignant Cancer ��_ 21 years WA Daunorubicin in children. Click Here 2009
ACTRN 12609000978268
 Relapsed or refactory solid tumours < 18 years VIC A Phase I study of LBH589 in paediatric patients with refractory solid tumours including CNS tumours. Click Here 2009
ADVL06B1 [COG-ADVL06B1] [NCT00674193]
 Embryonal Tumours < 17 years WA A pharmokinetic-pharmacodynamic study of Actinomycin D and Vincristine in children with cancer. Click Here 2009
ADVLO821
 Solid Tumours 6 months to 30 years NSW A Phase II study of IMC-A12 (Anti-IGF-1 Receptor monoclonal antibody IND#100947, NSC#742460) in children with relapsed/refractory solid tumours. Click Here 2009
AEWS0331 [NCT00020566] (CHW-NSW)
 Ewing's Sarcoma <50 years NSW European Ewing's tumour initiative of National Groups (Euro EWING 99). Click Here 2004
AEWS0331 [NCT00020566] (PMHC-WA)
 Ewing's Sarcoma <50 years WA European Ewing tumour working initiative of National Groups (Euro EWING 99). Click Here 2009
AEWS0521 [NCT00516295]
 Ewing's Sarcoma 1-29 years WA A phase II randomised study of Bevacizumab combined with Vincristine, Topotecan and Cyclophosphamide in patients with first recurrent Ewing's sarcoma. Click Here 2009
AEWS07B1 [COG-AEWS07B1]
 Ewing's Sarcoma No age limitations WA A COG protocol for collecting and banking Ewing Sarcoma specimens. Click Here 2009
AEWS07P1 [NCT00618813]
 Ewing's Sarcoma < 30 years WA A pilot study of chemotherapy intensification by adding Vincristine, Topotecan and Cyclophosphamide to standard chemotherapy agents with an interval compression schedule in newly diagnosed patients with localised Ewing's Sarcoma tumours. Click Here 2009
AMG 479 in Ewing's and Desmoplastic Tumours [NCT00563680]
 Refractory Ewing's Family Tumours and Desmoplastic Small Round Cell Tumours ��16 years VIC A Phase II study of AMG 479. Click Here Study ongoing closed for recruitment November 2009
AOST0331 [COG-AOST0331] (CHW-NSW)
 Osteosarcoma 5-40 years at diagnostic biopsy NSW A randomised trial of European and American Osteosarcoma groups to optimise treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Click Here 2006
AOST0331 [COG-AOST0331] (PMHC-WA)
 Osteosarcoma 5-40 years at diagnostic biopsy WA A randomised trial of European and American osteosarcoma groups to optimise treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Click Here 2005
AOST0331 [COG-AOST0331] (RCH-VIC)
 Osteosarcoma 5-40 years at diagnostic biopsy NSW A randomised trial of European and American osteosarcoma groups to optimise treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. Click Here 2006
AOST06B1 [COG-AOST06B1]
 Osteosarcoma No age limitations WA A COG protocol for collecting and banking osteosarcoma specimens. Click Here 2009
AOST06P1 [COG-AOST06P1] [NCT00742924]
 Osteogenic sarcoma (metastatic) ��_40 years WA A pilot study of feasibility and dose discovery analysis of zolendronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteogenic sarcoma. Click Here 2008
ARST0321 [NCT00068419]
 Desmoid Tumours (recurrent) < 18 years WA A Phase II study of Sulindac and Tamoxifen in patients with desmoids tumours that are recurrent or not amenable to standard therapy. Click Here 2008
ARST0331 [COG-ARST0331] [NCT00075582] (CHW-NSW)
 Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma < 50 years NSW Vincristine, Dactinomycin and lower doses of Cyclophosphamide with or without radiotherapy for patients with newly diagnosed low risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma Click Here 2005
ARST0331 [COG-ARST0331] [NCT00075582] (PMHC-WA)
 Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma < 50 years WA Vincristine, dactinomycin and lower doses of cyclophosphamide with or without radiotherapy for patients with newly diagnosed low risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma. Click Here 2005
ARST0331 [COG-ARST0331] [NCT00075582] (RCH-VIC)
 Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma < 50 years VIC Vincristine, dactinomycin and lower doses of cyclophosphamide with or without radiotherapy for patients with newly diagnosed low risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma Click Here 2006
ARST0332 [COG-ARST0332] [NCT00346164] (CHW-NSW)
 Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) < 30 years at diagnosis NSW Risk based treatment for paediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). Click Here 2007
ARST0332 [COG-ARST0332] [NCT00346164] (PMHC-WA)
 Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) < 30 years at diagnosis WA Risk based treatment for paediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). Click Here 2008
ARST0332 [COG-ARST0332] [NCT00346164] (RCH-VIC)
 Non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) < 30 years at diagnosis VIC Risk based treatment for paediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). Click Here 2008
ARST0431
 Rhabdomyosarcoma ��_49 years NSW Intensive, multi-agent therapy including dose-compressed cycles of lfosamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for patients with high-risk Rhabdomyosarcoma (RMS). Click Here 2006
ARST0531 [COG-ARST0531] [NCT00354835] (CHW-NSW)
 Rhabdomyosarcoma < 50 years NSW Randomised study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan for patients with intermediate-risk rhabdomyosarcoma. Click Here 2007
ARST0531 [COG-ARST0531] [NCT00354835] (PMHC-WA)
 Rhabdomyosarcoma < 50 years WA Randomised study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan for patients with intermediate-risk rhabdomyosarcoma. Click Here 2006
ARST0531 [COG-ARST0531] [NCT00354835] (RCH-VIC)
 Rhabdomyosarcoma < 50 years VIC Randomised study of vincristine, dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan for patients with intermediate-risk rhabdomyosarcoma. Click Here 2007
ASSG01-08: Sunitinib/XRT (PMCC-VIC)
 Resectable soft tissue sarcoma No age limitations VIC A phase Ib/II study of Sunitinib [a multi-targeted tyrosine kinase inhibitor] in combination with neoadjuvant radiation. Click Here 2009
ASSG01-08: Sunitinib/XRT (SCGH-WA)
 Resectable soft tissue sarcoma No age limitations WA A phase Ib/II study of Sunitinib [a multi-targeted tyrosine kinase inhibitor] in combination with neoadjuvant radiation. Click Here 2009
ASSG02-09: RFK ISKS (NSW-POWH)
 Sarcoma No age limitations NSW International Sarcoma Kindred Study, a world-first population-based, familial cancer study for adult-onset sarcomas. Click Here 2009
ASSG02-09: RFK ISKS (NSW-RPAH)
 Sarcoma No age limitations NSW International Sarcoma Kindred Study, a world-first population-based, familial cancer study for adult-onset sarcomas. Click Here 2009
ASSG02-09: RFK ISKS (QLD-PAH)
 Sarcoma No age limitations QLD International Sarcoma Kindred Study, a world-first population-based, familial cancer study for adult-onset sarcomas. Click Here 2009
ASSG02-09: RFK ISKS (QLD-WMC)
 Sarcoma No age limitations QLD International Sarcoma Kindred Study, a world-first population-based, familial cancer study for adult-onset sarcomas. Click Here 2009
ASSG02-09: RFK ISKS (VIC-PMCC)
 Sarcoma No age limitations VIC International Sarcoma Kindred Study, a world-first population-based, familial cancer study for adult-onset sarcomas. Click Here 2009
ASSG03-10: AYA PK (BMO-VIC)
 Osteosarcoma, Ewing's Sarcoma and Hodgkins Disease >1 year <40 years VIC A multi-institutional cross-discipline non-therapeutic study examining the pharmacokinetics and pharmacodynamics of doxorubicin in children, adolescents and young adults with newly diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma Click Here 2010
ASSG03-10: AYA PK (CHW-NSW)
 Osteosarcoma, Ewing's Sarcoma and Hodgkins Disease >1 year <40 years NSW A multi-institutional cross-discipline non-therapeutic study examining the pharmacokinetics and pharmacodynamics of doxorubicin in children, adolescents and young adults with newly diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma Click Here 2010
ASSG03-10: AYA PK (PMCC-VIC)
 Osteosarcoma, Ewing's Sarcoma and Hodgkins Disease > 1 year < 40 years VIC A multi-institutional cross-discipline non-therapeutic study examining the pharmacokinetics and pharmacodynamics of doxorubicin in children, adolescents and young adults with newly diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma Click Here 2010
ASSG03-10: AYA PK (RCH-QLD)
 Osteosarcoma, Ewing's Sarcoma and Hodgkins Disease >1 year <40 years VIC A multi-institutional cross-discipline non-therapeutic study examining the pharmacokinetics and pharmacodynamics of doxorubicin in children, adolescents and young adults with newly diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma Click Here 2010
ASSG03-10: AYA PK (RCH-VIC)
 Osteosarcoma, Ewing's Sarcoma and Hodgkins Disease >1 year < 40 years VIC A multi-institutional cross-discipline non-therapeutic study examining the pharmacokinetics and pharmacodynamics of doxorubicin in children, adolescents and young adults with newly diagnosed Osteosarcoma, Ewing Family of Tumours and Hodgkin Lymphoma Click Here 2010
ASSG04-09: IGF1R (POWH-NSW)
 Liposarcoma N/A NSW Effect and Mechanism of Targeting IGF1R on Radiosensitivity in Human Liposarcoma. N/A Closed
ASSG05-09: LAF/NCI LSYAA STF
 Sarcoma (also Melanoma and Colorectal) N/A VIC International retrospective analysis of outcomes for adolescent and young adult (AYA), sarcoma which is a combined retrospective pooled analysis of AYA sarcoma, melanoma and colorectal cancer randomised clinical trials, examining specifically, outcomes in the AYA age group compared to older or younger populations. N/A Pre-initiation
ASSG06-11: Sarcoma Lung Metastases Study
 Patients undergoing metastasectomy for metastatic sarcoma (bone and soft tissue) ��18 years VIC A prospective longitudinal cohort study describing quality of life in patients undergoing pulmonary metastasectomy (PM) for metastatic sarcoma. Click Here



 2011
ASSG07-09: Adjuvant Radiation Study
 Bone and soft tissue sarcoma in adult population N/A VIC This study has been designed to determine the pattern of utilization of adjuvant and radiation therapy in the treatment of bone and soft tissue sarcoma in adult populations in Australia. N/A Closed
COG ALTE03N1
 Key adverse events after childhood cancer diagnosis <21 VIC Key adverse events after childhood cancer diagnosed <21 years including myocardial infarction, ischaemic stroke, subsequent malignant neoplasm and avascular necrosis: genetics/epidemiology study. Click Here 2007
COG-AREN 0321NCT00335556
 Renal Cell, Wilms Tumour and other. (includes Sarcoma) Localised and Metastatic 0-29 years VIC Phase II trial studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumours. Click Here 2009
GCT Study [NCT00680992] (PMCC-VIC)
 Giant Cell Tumour of bone ��18 years VIC An open-label, multi-centre, Phase II study of Denosumab. Click Here 2009
GCT Study [NCT00680992] (SCGH-WA)
 Giant Cell Tumour of bone ��18 years WA An open-label, multi-centre, Phase II study of Denosumab. Click Here 2009
GSK/EORTC VEG110727/62072 'Palette' [NCT00753688] (ACC-SA)
 Advanced Soft-tissue Sarcoma (Metastatic) ��18 years SA A Phase III randomized double blind placebo-controlled study assessing the activity of Pazopanib, a VEGF tyrosine kinase inhibitor. In patients whose disease has progressed during or following prior therapy. Click Here Study ongoing closed for recruitment January 2010
GSK/EORTC VEG110727/62072 'Palette' [NCT00753688] (PAH-QLD)
 Advanced Soft-tissue Sarcoma (Metastatic) ��18 years QLD A Phase III randomized double blind placebo-controlled study assessing the activity of Pazopanib, a VEGF tyrosine kinase inhibitor. In patients whose disease has progressed during or following prior therapy. Click Here Study ongoing closed for recruitment January 2010
GSK/EORTC VEG110727/62072 'Palette' [NCT00753688] (POWH-NSW)
 Advanced Soft-tissue Sarcoma (Metastatic) ��18 years NSW A Phase III randomized double blind placebo-controlled study assessing the activity of Pazopanib, a VEGF tyrosine kinase inhibitor. In patients where disease has progressed during or following prior therapy. Click Here Study ongoing closed for recruitment January 2010
GSK/EORTC VEG110727/62072 'Palette' [NCT00753688] (RHH-TAS)
 Advanced Soft-tissue Sarcoma (Metastatic) ��18 years TAS A Phase III randomized double blind placebo-controlled study assessing the activity of Pazopanib, a VEGF tyrosine kinase inhibitor. In patients whose disease has progressed during or following prior therapy. Click Here Study ongoing closed for recruitment January 2010
GSK/EORTC VEG110727/62072 'Palette' [NCT00753688] (SCGH-WA)
 Advanced Soft-tissue Sarcoma (Metastatic) ��18 years WA A Phase III randomized double blind placebo-controlled study assessing the activity of Pazopanib, a VEGF tyrosine kinase inhibitor. In patients whose disease has progressed during or following prior therapy. Click Here Study ongoing closed for recruitment January 2010
Infinity IPI-926
 Conventional Chondrosarcoma
 18 years or older VIC A phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients with metastatic or Locally Advanced (Unresectable) chondrosarcoma
 Click Here
 Feb-11
Maintenance AP23573 'Succeed' [NCT00538239] (POWH-NSW)
 Soft-tissue and bone sarcoma ��13 years NSW A Phase III randomized double blind placebo-controlled study assessing the activity of Deforolimus (AP23573) as maintenance therapy for patients with metastatic soft tissue or bone sarcomas who have not progressed on prior chemotherapy. Click Here Study ongoing closed for recruitment January 2010
Maintenance AP23573 'Succeed' [NCT00538239] (RPAH-NSW)
 Soft-tissue and bone sarcoma ��13 years NSW A Phase III randomized double blind placebo-controlled study assessing the activity of Deforolimus (AP23573) as maintenance therapy for patients with metastatic soft tissue or bone sarcomas who have not progressed on prior chemotherapy. Click Here Study ongoing closed for recruitment January 2010
Maintenance AP23573 'Succeed' [NCT00538239] (TCH-ACT)
 Soft-tissue and bone sarcoma ��13 years ACT A Phase III randomized double blind placebo-controlled study assessing the activity of Deforolimus (AP23573) as maintenance therapy for patients with metastatic soft tissue or bone sarcomas who have not progressed on prior chemotherapy. Click Here Study ongoing closed for recruitment January 2010
MERCK MK0869
 Paediatric patients receiving emetogenic chemotherapy 6 months to 17 years VIC A multi-centre, open-label, 5-part study to evaluate the pharmacokinetics, safety, and tolerability of Aprepitant and Fosaprepitant Dimeglumine in paediatric patients receiving emetogenic chemotherapy. Click Here 2009
P04720 [NCT00617890] (PAH-QLD)
 Osteosarcoma and Ewing's Sarcoma ��11 years QLD A study to determine the activity of SCH 717454 in subjects with osteosarcoma or Ewing's sarcoma where there has been a relapse after standard systematic therapy. Click Here 2009
P04720 [NCT00617890] (SCH-NSW)
 Osteosarcoma and Ewing's Sarcoma ��13 years NSW A study to determine the activity of SCH 717454 in subjects with osteosarcoma or Ewing's sarcoma that has relapsed after standard systematic therapy. Click Here 2009
Pfizer 4021020 [NCT00560235] (RCH-VIC)
 A Phase 1/Phase 2 Study of CP-751, 871 in patients aged 10 or over with relapsed and/or refractory Ewing's Sarcoma Family of Tumours. 10-18 years VIC Pfizer 4021020 A Phase1/Phase2 Study of CP. Click Here Study ongoing closed for recruitment
Pfizer 4021020 [NCT00560235] (SCH-NSW)
 A Phase 1/Phase 2 Study of CP-751, 871 in patients aged 10 or over with Relapsed and/or Refractory Ewing's Sarcoma Family of Tumours. 10-18 years NSW Pfizer 4021020 A Phase1/Phase2 Study of CP. Click Here Study ongoing closed for recruitment
RCH RST06
 Recurrent Solid Tumours (high risk) <25 years VIC A safety and feasibility study of active immunotherapy in patients with high risk recurrent solid tumours using autologous dendritic cells pulsed with tumour lysates. 2007
SARC/ ROCHE IGF 1R [SARC011/NO21157] [NCT00642941]
 Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and other Sarcomas >2 years VIC A Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory sarcomas. Click Here 2008
Sunitinib/XRT [ASSG01-08] [NCT00753727] (PMCC-VIC)
 Resectable Soft-tissue Sarcoma <16 years VIC A Phase Ib/II study of Sunitinib in combination with neoadjuvant radiation. Click Here 2009
Sunitinib/XRT [ASSG01-08] [NCT00753727] (SCGH-WA)
 Resectable Soft-tissue Sarcoma <16 years WA A Phase Ib/II study of Sunitinib in combination with neoadjuvant radiation. Click Here 2009

 

Search for a Clinical Study


Last update: 22-Jul-2011 11:23 AM